Design Therapeutics/$DSGN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Design Therapeutics
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.
- Ticker
- $DSGN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 60
- Headquarters
- Carlsbad, United States
- Website
- www.designtx.com
DSGN Metrics
BasicAdvanced
$635M
-
-$1.21
1.75
-
Price and volume
Market cap
$635M
Beta
1.75
52-week high
$17.25
52-week low
$7.24
Average daily volume
434K
Financial strength
Current ratio
16.777
Quick ratio
16.494
Long term debt to equity
0.009
Total debt to equity
0.012
Profitability
EBITDA (TTM)
-81.282
Management effectiveness
Return on assets (TTM)
-23.88%
Return on equity (TTM)
-36.87%
Valuation
Price to book
3.13
Price to tangible book (TTM)
3.13
Price to free cash flow (TTM)
-10.265
Free cash flow yield (TTM)
-9.74%
Free cash flow per share (TTM)
-0.966
Growth
Earnings per share change (TTM)
1.58%
3-year earnings per share growth (CAGR)
-2.32%
What the Analysts think about DSGN
Analyst ratings (Buy, Hold, Sell) for Design Therapeutics stock.
Analyst projections of the future price of Design Therapeutics stock.
Bulls say / Bears say
DT-216P2 showed biological activity in blood and muscle, with frataxin increases and encouraging changes in clinical measures after four weeks. If the effects hold up in larger, longer studies, the programme could offer a disease-modifying treatment for Friedreich ataxia. (Design Therapeutics)
The company had $208.6 million in cash and securities at the end of September 2026, giving it funding to advance its clinical programmes and reach upcoming data milestones. (Design Therapeutics)
Design has begun dosing patients in a Phase 1 trial of DT-818 for DM1, adding a clinical programme beyond its lead Friedreich ataxia drug. A positive readout could support the case that its GeneTAC approach can be applied across more than one inherited disease. (Design Therapeutics)
The reported clinical improvements came from just four patients at the highest dose after four weeks of treatment. Those early findings may not hold up in the planned longer study or establish meaningful benefit in a larger population. (Design Therapeutics)
The Phase 2 biomarker readout for DT-168 in FECD was delayed to 2027 because of a supply delay for its eye-drop containers. This pushes back an important test of the pipeline beyond the lead FA programme. (Design Therapeutics)
Design has no product sales and continues to lose money, with a $20.3 million net loss in the third quarter of 2026. Its cash will be consumed by development costs, and the company says it may need further funding that could dilute shareholders. (U.S. Securities and Exchange Commission)
Data summarised monthly by Lightyear AI. Last updated on 13 Nov 2026.
DSGN Financial Performance
Revenues and expenses
DSGN Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing DSGN
Fund name | Fund size | $DSGN weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.3B | 0.04% |
iShares Nasdaq US Biotechnology£BTEK | $1.3B | 0.04% |
SPDR Russell 2000 US Small Cap€R2US | $4.7B | 0.01% |
SPDR Russell 2000 US Small Cap£R2SC | $4.7B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.